Acelyrin (NASDAQ: SLRN) stock is down 58% overnight. SLRN stock fell so badly because there was an announcement about one of the company’s drug candidates. That news being that, well, no, sadly, it doesn’t work. Another way of putting this is that they managed to get that IPO away in time, before this news was known, didn’t they?
The news itself: “ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced top-line results from Part B of a Phase 2b/3 trial evaluating izokibep for the treatment of moderate-to-severe Hidradenitis Suppurativa (HS). The primary endpoint of HiSCR75 at week 16 did not meet statistical significance. However, response rates for izokibep showed early HiSCR100 responses, a clear dose-effect supported by both pharmacokinetic exposures and HiSCR responses favoring 160mg weekly dosing, and no evidence of safety or tolerability limitation.”
Like everything in this field this all gets very complex very quickly. There’s information in there which might be worth further exploration. But they’ve not passed this test this time - thus that effect on the SLRN stock price.

Acelyrin stock price from Google Finance
This isn;t the end for Acelyrin, they’ve a pipeline rather than just the one drug candidate: “Acelyrin (NASDAQ:SLRN) is a late-stage clinical biopharma aiming to fast-track the development and commercialization of therapies for diseases linked to overactive immune responses. Their portfolio includes several clinical-stage candidates targeting multi-billion-dollar markets. The lead product, izokibep, is a small protein therapeutic in Phase 2b/3 trials for multiple immunological conditions. Acelyrin also has ongoing trials for other candidates like lonigutamab and SLRN-517 for thyroid eye disease and chronic urticaria, respectively.”
That makes valuation a little difficult of course. For we can think that if the first candidate fails - or looks like it fails - then how good are the others? On the other hand we can take comfort from there being others given that the first didn’t work. What would actually be worst is if it was some failure in the testing process that caused this problem. Which is an idea that might be worth chewing over.
It’s not a good end to the first six months as a public company - the IPO was only back in May after all.



